Pharma BD Deal Intelligence
Total loss: iniparib was never actually a PARP inhibitor, failed every subsequent Phase III/II trial, and was fully written off for $285M in 2013.
Full analysis, sources & comparables →A board member called it 'a landmark transaction for 2009,' but the article noted analysts view the deal as a 'long-term gamble' with financial benefits…
Sanofi's iniparib (BSI-201), the centerpiece of the BiPar acquisition, flunked its Phase III triple-negative breast cancer trial, missing co-primary endpoints…
'Downfall of Iniparib: A PARP Inhibitor That Doesn't Inhibit PARP After All' — the asset Sanofi bought from BiPar lacked characteristics typical of the PARP…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Sanofi-aventis agreed to acquire BiPar Sciences for up to $500M, contingent on milestones, to gain the PARP inhibitor BSI-201 (iniparib) in oncology.
Total loss: iniparib was never actually a PARP inhibitor, failed every subsequent Phase III/II trial, and was fully written off for $285M in 2013.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi-Aventis / BiPar Sciences, Inc. (this deal) | 2009 | $500M | 8 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Sanofi-Aventis / Merial Limited (Merck's 50% interest) | 2009 | $4.0B | 65 |
| Sanofi-Aventis / Acambis plc | 2008 | $548M | 36 |
| Sanofi-Aventis / Shantha Biotechnics Limited | 2009 | $784M | 34 |
| Sanofi-Aventis / Fovea Pharmaceuticals SA | 2009 | $541M | 23 |
| Sanofi-Aventis / ImmunoGen Inc. | 2005 | $18M | — |
← Browse all deals · How we score deals
More: 2009 deals · Sanofi-Aventis deals